A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PERSPECTIVE
- Sponsors Novartis Pharmaceuticals
- 07 Mar 2017 Planned End Date changed from 1 Jul 2021 to 14 Jul 2021.
- 07 Mar 2017 Planned primary completion date changed from 1 Jul 2021 to 12 Jul 2021.
- 05 Dec 2016 Status changed from not yet recruiting to recruiting.